Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more
Revolution Medicines Inc (RVMD) - Net Assets
Latest net assets as of September 2025: $1.60 Billion USD
Based on the latest financial reports, Revolution Medicines Inc (RVMD) has net assets worth $1.60 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.25 Billion) and total liabilities ($655.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.60 Billion |
| % of Total Assets | 70.91% |
| Annual Growth Rate | 142.95% |
| 5-Year Change | 377.21% |
| 10-Year Change | N/A |
| Growth Volatility | 686.03 |
Revolution Medicines Inc - Net Assets Trend (2017–2024)
This chart illustrates how Revolution Medicines Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Revolution Medicines Inc (2017–2024)
The table below shows the annual net assets of Revolution Medicines Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.27 Billion | +24.04% |
| 2023-12-31 | $1.83 Billion | +166.52% |
| 2022-12-31 | $685.19 Million | +13.71% |
| 2021-12-31 | $602.57 Million | +26.94% |
| 2020-12-31 | $474.68 Million | +211.19% |
| 2019-12-31 | $152.53 Million | +57.81% |
| 2018-12-31 | $96.66 Million | +2033.28% |
| 2017-12-31 | $4.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revolution Medicines Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 166986800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.00K | 0.00% |
| Other Comprehensive Income | $1.32 Million | 0.06% |
| Other Components | $4.00 Billion | 176.66% |
| Total Equity | $2.27 Billion | 100.00% |
Revolution Medicines Inc Competitors by Market Cap
The table below lists competitors of Revolution Medicines Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ritchie Bros Auctioneers
TO:RBA
|
$17.27 Billion |
|
Weyerhaeuser Company
NYSE:WY
|
$17.28 Billion |
|
SUV
XETRA:SUV
|
$17.29 Billion |
|
China Petroleum & Chemical Corp Class H
PINK:SNPMF
|
$17.30 Billion |
|
Credo Technology Group Holding Ltd
NASDAQ:CRDO
|
$17.22 Billion |
|
Nextracker Inc. Class A Common Stock
NASDAQ:NXT
|
$17.18 Billion |
|
Ajinomoto Co., Inc.
F:AJI0
|
$17.16 Billion |
|
Lululemon Athletica Inc.
NASDAQ:LULU
|
$17.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revolution Medicines Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,826,194,000 to 2,265,204,000, a change of 439,010,000 (24.0%).
- Net loss of 600,093,000 reduced equity.
- Share repurchases of 5,029,000 reduced equity.
- New share issuances of 846,348,000 increased equity.
- Other comprehensive income increased equity by 777,000.
- Other factors increased equity by 197,007,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-600.09 Million | -26.49% |
| Share Repurchases | $5.03 Million | -0.22% |
| Share Issuances | $846.35 Million | +37.36% |
| Other Comprehensive Income | $777.00K | +0.03% |
| Other Changes | $197.01 Million | +8.7% |
| Total Change | $- | 24.04% |
Book Value vs Market Value Analysis
This analysis compares Revolution Medicines Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 797.97x to 7.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.12 | $99.13 | x |
| 2018-12-31 | $2.65 | $99.13 | x |
| 2019-12-31 | $4.18 | $99.13 | x |
| 2020-12-31 | $7.13 | $99.13 | x |
| 2021-12-31 | $8.28 | $99.13 | x |
| 2022-12-31 | $8.50 | $99.13 | x |
| 2023-12-31 | $16.14 | $99.13 | x |
| 2024-12-31 | $13.50 | $99.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revolution Medicines Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-26.49%) is above the historical average (-112.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -686.98% | 0.00% | 0.00x | 3.33x | $-31.58 Million |
| 2018 | -43.23% | -207.24% | 0.12x | 1.76x | $-51.45 Million |
| 2019 | -31.25% | -95.25% | 0.23x | 1.45x | $-62.92 Million |
| 2020 | -22.79% | -251.63% | 0.08x | 1.20x | $-155.63 Million |
| 2021 | -31.05% | -636.58% | 0.04x | 1.22x | $-247.35 Million |
| 2022 | -36.30% | -702.95% | 0.04x | 1.18x | $-317.22 Million |
| 2023 | -23.89% | -3768.28% | 0.01x | 1.13x | $-618.99 Million |
| 2024 | -26.49% | 0.00% | 0.00x | 1.13x | $-826.61 Million |
Industry Comparison
This section compares Revolution Medicines Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revolution Medicines Inc (RVMD) | $1.60 Billion | -686.98% | 0.41x | $17.25 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |